Trials / Completed
CompletedNCT01727128
Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment
A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairmen
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To assess pharamcokinetics, safety and tolerability of a single oral dose of BKM120 in subjects with mild, moderate and severe hepatic impairment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BKM120 |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2012-11-15
- Last updated
- 2020-12-09
Locations
3 sites across 3 countries: Bulgaria, Germany, Russia
Source: ClinicalTrials.gov record NCT01727128. Inclusion in this directory is not an endorsement.